Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Happihoito lapsille ja nuorille, joilla on Downin oireyhtymä ja obstruktiivinen uniapnea (DOSA)

perjantai 25. syyskuuta 2026 päivittänyt: Susan Redline, Brigham and Women's Hospital

Satunnaistettu kontrollikoe happiterapiasta lapsilla ja nuorilla, joilla on Downin oireyhtymä ja obstruktiivinen uniapnea

The purpose of this study is to assess whether oxygen supplementation during sleep improves working memory and other clinical and patient-reported outcomes among children who have Down Syndrome (DS) with moderate to severe Obstructive Sleep Apnea (OSA).

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

This will be a randomized, single-blind 6-month Phase-2 clinical trial that compares the impact of oxygen therapy during sleep on measures of cognition, behavior, quality of life, cardiac structure and function, and sleep in children with Down Syndrome(DS) with moderate to severe obstructive sleep apnea.

The proposed study will involve participation of children and their caregivers. Children will be recruited from each site's sleep clinics and laboratories, Down syndrome clinics and otolaryngology clinics. Community recruitment will be coordinated with local Down Syndrome Associations.

Children who agree to participate in the study will be screened for eligibility based on history, physical examination, and review of medical records including history of congenital heart disease and Pulmonary Hypertension (PHTN), and use of Continuous Positive Airway Pressure (CPAP). Children eligible for the study are those with persistent obstructive apnea after adenotonsillectomy or children with obstructive sleep apnea without adenotonsillar hypertrophy or in situations when parents refuse adenotonsillectomy.. The enrollment PSG eligibility will be determined by central scoring of either a research Polysomnography (PSG). In addition to an oxygen titration PSG, which determines responsiveness to oxygen, participants will be asked to wear a wrist actigraph and undergo neurocognitive testing, echocardiography, physical examination, anthropometry, and venipuncture. Caregivers will complete questionnaires to assess their child's emotional, physical, social, and school functioning, sleep quality; child's behavior and cognitive function, and will complete a sleep diary that is used concurrently with their child's use of a wrist actigraph. The latter includes caregiver completion of the "Behavior Rating Inventory of Executive Function" (BRIEF2), a co-primary outcome.

At 3 months, caregivers will complete the BRIEF2. At 6 months, all baseline studies and a PSG will be repeated.

At baseline, demographic data will be collected, including information on residential address (for use in geocoding).

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

230

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

    • California
      • Los Angeles, California, Yhdysvallat, 90027
        • Rekrytointi
        • Children's Hospital of Los Angeles
        • Ottaa yhteyttä:
        • Päätutkija:
          • Sally Ward, MD
    • Michigan
      • Ann Arbor, Michigan, Yhdysvallat, 48109
        • Rekrytointi
        • University of Michigan, Ann Arbor Hospital
        • Ottaa yhteyttä:
        • Päätutkija:
          • Ronald Chervin, MD
    • Ohio
      • Cincinnati, Ohio, Yhdysvallat, 45229
        • Rekrytointi
        • Cincinnati Children's Hospital Medical Center
        • Päätutkija:
          • Raouf Amin, MD
        • Ottaa yhteyttä:
      • Cleveland, Ohio, Yhdysvallat, 44106
        • Rekrytointi
        • Rainbow Babies and Children's Hospital, Case Medical Center
        • Ottaa yhteyttä:
        • Päätutkija:
          • Sally Ibrahim, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Yhdysvallat, 19104
        • Rekrytointi
        • Children's Hospital of Philadelphia
        • Ottaa yhteyttä:
        • Päätutkija:
          • Christopher Cielo, MD
    • Virginia
      • Norfolk, Virginia, Yhdysvallat, 23507
        • Rekrytointi
        • East Virginia Medical Center
        • Ottaa yhteyttä:
        • Päätutkija:
          • Cristina Baldassari, MD
    • Washington
      • Seattle, Washington, Yhdysvallat, 98105

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

5 vuotta - 18 vuotta (Lapsi, Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  1. Ages 5.0 to 17.9 years at the time of screening

  2. Children with OSA and obstructive apnea hypopnea index (OAHI) ≥5/hour.

  3. Absence of clinically significant hypoxia defined as oxygen saturation <88% for 5 minutes or episodic desaturation to 60% as these levels would otherwise identify children eligible to routinely receive oxygen.

  4. Favorable response to oxygen therapy (allowing randomization) will be defined as follows:

    1. Oxygen saturation nadir >92% and
    2. Decrease in obstructive index < 5 / hour or by > 50% from screening PSG
    3. Reaching an optimum oxygen flow which is defined as the flow that achieves the lowest level of AHI with maximum CO2 level less than 65 mmHg observed for 5 consecutive minutes and or an increase in CO2 by less than 15 points above baseline. The above criteria are observed while the patient spends a minimal of 30 minutes in the supine position and at least one cycle of rapid eye movement (REM) sleep.
    4. Oxygen flow required does not exceed 3.0 LPM and does not exceed a FiO2 > 40 %.
  5. Willingness to comply with all study procedures and available for duration of study.

  6. At baseline the participant attempts to perform the neuropsychological tests

Exclusion Criteria:

  1. Current CPAP use with documented compliance(> 4 hrs/ night; > 70% of nights).
  2. Oxygen saturation < 90% at rest during wakefulness.
  3. Chronic daytime or nighttime use of supplemental oxygen.
  4. Smoker in the child's bedroom.
  5. Unrepaired congenital heart disease.
  6. Moderate to severe pulmonary hypertension requiring treatment with oxygen and or pulmonary vasodilator.
  7. Unable to participate in a PSG.
  8. Individuals who develop alveolar hypoventilation with oxygen as previously defined.
  9. Other severe chronic diseases determined by their provider as making them poor study candidates.
  10. Enrolled or planning to enroll in another study that may conflict with protocol requirements or confound results in this trial.
  11. Documented clinically significant untreated hypothyroidism
  12. Children with adenotonsillar hypertrophy who are candidates for adenotonsillectomy and parents agree to the surgery.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kolminkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Active Comparator: Oxygen plus supportive care (OXT)

Nocturnal oxygen therapy plus providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.

Active nocturnal oxygen concentrator

Ei väliintuloa: Supportive care (SC)

Providing patient with healthy sleep habits materials, healthy diet materials and nasal dilators.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory score
Aikaikkuna: Baseline and 6 months

Change from baseline in the Behavior Rating Inventory of Executive Function 2 (BRIEF2) working memory score (BRIEF2wm). The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 months
Differential Ability Scales - 2nd Edition (DAS-II) T-score.
Aikaikkuna: Baseline and 6 months

Change from baseline in the Differential Ability Scales - 2nd Edition (DAS-II) recognition of pictures (DAS2RoP) T-score. The score ranges from 10-90. A higher score is a better outcome.

Baseline and 6 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw score
Aikaikkuna: Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Total raw score. The score ranges from 0-64. A higher score is a better outcome.

Baseline and 6 Months
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw score
Aikaikkuna: Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Verbal raw score. The score ranges from 0-30. A higher score is a better outcome.

Baseline and 6 Months
Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw score
Aikaikkuna: Baseline and 6 Months

Change from baseline of Stanford-Binet Intelligence Scales, 5th edition (SB-5) Working Memory Non Verbal raw score. The score ranges from 0-34. A higher score is a better outcome.

Baseline and 6 Months
Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw score
Aikaikkuna: Baseline and 6 Months

Change from baseline in Differential Ability Scales-2 (DAS-II) Recall of Digits Forward raw score. The score ranges from 0-38. A higher score is a better outcome.

Baseline and 6 Months
Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completed
Aikaikkuna: Baseline and 6 Months

Change from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) adjusted total errors based on stages completed

Baseline and 6 Months
Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)
Aikaikkuna: Baseline and 6 Months

Change from baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI)

Baseline and 6 Months
Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw score
Aikaikkuna: Baseline and 6 Months

Change from baseline in Developmental Neuropsychological Assessment 2nd Edition (NEPSY-II) verbal fluency test raw score. Range-N/A

Baseline and 6 Months
Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-score
Aikaikkuna: Baseline and 6 Months

Change from baseline in Observer Memory Questionnaire - Parent Form (OMQ-PF) total T-score. The score ranges from 0-135. A higher score is a better outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate)
Aikaikkuna: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for subscales (Inhibit, Self-Monitor, Shift, Emotional Control, Initiate).

Baseline and 6 Months
Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).
Aikaikkuna: Baseline and 6 Months

Change from baseline in Child Behavior Checklist (CBCL) T-scores for domains (Internalizing, Externalizing, Total Problems).

Baseline and 6 Months
Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)
Aikaikkuna: Baseline and 6 Months

Change from baseline in Child Behavior Checklist (CBCL) T-scores for subscales (Attention Problems, Thought Problems, Rule-Breaking Behaviors, Aggressive Behaviors)

Baseline and 6 Months
KIDSCREEN-27 T-score
Aikaikkuna: Baseline and 6 Months

Change from baseline in KIDSCREEN-27 T-score, including domains of: physical well-being; psychological well-being; autonomy and parent relations; social support and peers; school environment. Range-N/A

Baseline and 6 Months
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-score
Aikaikkuna: Baseline and 6 Months

Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance T-score. The score ranges from 28.7-85.6. A higher score is a worse outcome.

Baseline and 6 Months
Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score
Aikaikkuna: Baseline and 6 Months

Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score. The score ranges from 37.9-86.6. A higher score is a worse outcome.

Baseline and 6 Months
Presence of right ventricular hypertension
Aikaikkuna: Baseline and 6 Months

Presence of right ventricular hypertension as measured by tricuspid regurgitation continuous wave peak velocity (defined as a ratio of pulmonary artery pressure / systolic arterial pressure (PAP/SAP) >1/3); interventricular septal flattening as measured by eccentricity index (defined as systolic ratio of >1.25)

Baseline and 6 Months
Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw score
Aikaikkuna: Baseline and 6 Months

Change from baseline of Wechsler Intelligence Scale (WISC) for Children 5th edition (WISC-5) Cancellation raw score. The score ranges from 0-128. A higher score is a better outcome.

Baseline and 6 Months
Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw score
Aikaikkuna: Baseline and 6 Months

Change from baseline in Wechsler Preschool and Primary Scale of Intelligence 4th edition (WPPSI-4) Cancellation task raw score (if unable to complete Wechsler Intelligence Scale 5th edition Cancellation test). The score ranges from 0-96. A higher score is a better outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain.
Aikaikkuna: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Behavior Regulation Index (BRI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain.
Aikaikkuna: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Emotional Recognition Index (ERI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain.
Aikaikkuna: Baseline and 6 Months

Change from baseline in Behavior Rating Inventory of Executive Function 2 (BRIEF2) T-scores for Cognitive Regulation Index (CRI) domain. The score ranges from 35-90. A higher score is a worse outcome.

Baseline and 6 Months
7-day actigraphy measurement of sleep efficiency
Aikaikkuna: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of sleep efficiency

Baseline and 6 Months
7-day actigraphy measurement of time wake after sleep onset
Aikaikkuna: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of time wake after sleep onset

Baseline and 6 Months
7-day actigraphy measurement of sleep fragmentation
Aikaikkuna: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of sleep fragmentation

Baseline and 6 Months
7-day actigraphy measurement of total sleep duration
Aikaikkuna: Baseline and 6 Months

Change from baseline in 7-day actigraphy measurement of total sleep duration

Baseline and 6 Months
Polysomnography (PSG) AHI parameter
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) AHI parameter. The score ranges from 0- >40. A higher score is a worse outcome.

Baseline and 6 Months
Polysomnography (PSG) percentage time of O2 <90 % parameter
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) percentage time of O2 <90 % parameter

Baseline and 6 Months
Polysomnography (PSG) sleep apnea associated hypoxic burden parameter
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) sleep apnea associated hypoxic burden, parameter

Baseline and 6 Months
Polysomnography (PSG) end-tidal CO2 level, parameter
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) end-tidal CO2 parameter.

Baseline and 6 Months
Polysomnography (PSG) -based measure of sleep stages
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of sleep stages. Range- N/A

Baseline and 6 Months
Polysomnography (PSG) -based measure of EEG power bands
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of EEG power bands

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle morphology
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle morphology

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle numbers
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle numbers

Baseline and 6 Months
Polysomnography (PSG) -based measure of spindle density
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of spindle density

Baseline and 6 Months
Polysomnography (PSG) -based measure of slow wave oscillations
Aikaikkuna: Baseline and 6 Months

Change from baseline in Polysomnography (PSG) -based measure of slow wave oscillations

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)
Aikaikkuna: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral E and A wave (E:A ratio)

Baseline and 6 Months
Left ventricular diastolic function as measured by E wave deceleration time
Aikaikkuna: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by E wave deceleration time

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')
Aikaikkuna: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral septal and lateral e' and a' (E/e')

Baseline and 6 Months
Left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation time
Aikaikkuna: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Mitral lateral tissue Doppler isovolumic relaxation time

Baseline and 6 Months
Left ventricular diastolic function as measured by Pulmonary vein A wave reversal duration
Aikaikkuna: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Pulmonary vein A wave reversal duration

Baseline and 6 Months
Left ventricular diastolic function as measured by Left atrial volume
Aikaikkuna: Baseline and 6 Months

Change from baseline in left ventricular diastolic function as measured by Left atrial volume

Baseline and 6 Months

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Susan Redline, Brigham and Women's Hospital
  • Päätutkija: Raouf Amin, Children's Hospital Medical Center, Cincinnati

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 24. lokakuuta 2023

Ensisijainen valmistuminen (Arvioitu)

Tiistai 30. marraskuuta 2027

Opintojen valmistuminen (Arvioitu)

Torstai 30. joulukuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 17. elokuuta 2023

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 12. syyskuuta 2023

Ensimmäinen Lähetetty (Todellinen)

Torstai 21. syyskuuta 2023

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 30. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 25. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • 2023P000062

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Yhdysvalloissa valmistettu ja sieltä viety tuote

Joo

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .